138 related articles for article (PubMed ID: 31685762)
1. Systems Pathology of Neuropathic Pain and Fibromyalgia.
Ueda H
Biol Pharm Bull; 2019; 42(11):1773-1782. PubMed ID: 31685762
[TBL] [Abstract][Full Text] [Related]
2. LPA receptor signaling as a therapeutic target for radical treatment of neuropathic pain and fibromyalgia.
Ueda H
Pain Manag; 2020 Jan; 10(1):43-53. PubMed ID: 31852400
[TBL] [Abstract][Full Text] [Related]
3. Lysophosphatidic Acid Receptor 1- and 3-Mediated Hyperalgesia and Hypoalgesia in Diabetic Neuropathic Pain Models in Mice.
Ueda H; Neyama H; Matsushita Y
Cells; 2020 Aug; 9(8):. PubMed ID: 32824296
[TBL] [Abstract][Full Text] [Related]
4. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain.
Ma L; Uchida H; Nagai J; Inoue M; Chun J; Aoki J; Ueda H
Mol Pain; 2009 Nov; 5():64. PubMed ID: 19912636
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice.
Uchida H; Nagai J; Ueda H
Mol Pain; 2014 Nov; 10():71. PubMed ID: 25411045
[TBL] [Abstract][Full Text] [Related]
6. An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model.
Ma L; Nagai J; Chun J; Ueda H
Mol Pain; 2013 Jun; 9():29. PubMed ID: 23773289
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid and its receptor LPA
Srikanth M; Chew WS; Hind T; Lim SM; Hay NWJ; Lee JHM; Rivera R; Chun J; Ong WY; Herr DR
Eur J Pharmacol; 2018 Dec; 841():49-56. PubMed ID: 30321532
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid receptors (LPARs): Potential targets for the treatment of neuropathic pain.
Velasco M; O'Sullivan C; Sheridan GK
Neuropharmacology; 2017 Feb; 113(Pt B):608-617. PubMed ID: 27059127
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic mechanisms of lipid mediator lysophosphatidic acid in chronic pain.
Ueda H
Prog Lipid Res; 2021 Jan; 81():101079. PubMed ID: 33259854
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
[TBL] [Abstract][Full Text] [Related]
11. Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain.
Lin ME; Rivera RR; Chun J
J Biol Chem; 2012 May; 287(21):17608-17617. PubMed ID: 22461625
[TBL] [Abstract][Full Text] [Related]
12. Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodents.
Murai N; Hiyama H; Kiso T; Sekizawa T; Watabiki T; Oka H; Aoki T
Neuropharmacology; 2017 Nov; 126():97-107. PubMed ID: 28859883
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidic acid as the initiator of neuropathic pain.
Ueda H
Biol Pharm Bull; 2011; 34(8):1154-8. PubMed ID: 21804198
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic acid signaling via LPA
Fukushima K; Takahashi K; Yamasaki E; Onishi Y; Fukushima N; Honoki K; Tsujiuchi T
Exp Cell Res; 2017 Mar; 352(1):139-145. PubMed ID: 28189636
[TBL] [Abstract][Full Text] [Related]
15. Proliferation of mouse endometrial stromal cells in culture is highly sensitive to lysophosphatidic acid signaling.
Aikawa S; Kano K; Inoue A; Aoki J
Biochem Biophys Res Commun; 2017 Feb; 484(1):202-208. PubMed ID: 28073697
[TBL] [Abstract][Full Text] [Related]
16. Involvement of LPA1 receptor signaling in cerebral ischemia-induced neuropathic pain.
Halder SK; Yano R; Chun J; Ueda H
Neuroscience; 2013 Apr; 235():10-5. PubMed ID: 23318243
[TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidic acid LPA
Ueda H; Neyama H; Sasaki K; Miyama C; Iwamoto R
Neurobiol Pain; 2019; 5():100020. PubMed ID: 31194070
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid and signaling in sensory neurons.
Oude Elferink RP; Bolier R; Beuers UH
Biochim Biophys Acta; 2015 Jan; 1851(1):61-5. PubMed ID: 25218302
[TBL] [Abstract][Full Text] [Related]
19. LPA
Dancs PT; Ruisanchez É; Balogh A; Panta CR; Miklós Z; Nüsing RM; Aoki J; Chun J; Offermanns S; Tigyi G; Benyó Z
FASEB J; 2017 Apr; 31(4):1547-1555. PubMed ID: 28069828
[TBL] [Abstract][Full Text] [Related]
20. LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease.
Yang XY; Zhao EY; Zhuang WX; Sun FX; Han HL; Han HR; Lin ZJ; Pan ZF; Qu MH; Zeng XW; Ding Y
Neurol Sci; 2015 Nov; 36(11):2027-33. PubMed ID: 26169757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
